 Allakos Inc NASDAQ: ALLK announced its results from Enigma II, Phase III placebo-controlled, double-blind clinical research of lirentelimab on people battling EG eosinophilic gastritis and went up by around 80. The company also concluded its Kryptos study of lirentelimab on people with biopsy-confirmed EOE eosinophilic esophagitis. 